Mr. Vu brings over 20 years of corporate and financial strategy, investment banking and public company experience. From October 2024 through February 2025, Mr. Vu served as a Venture Partner of ZhongMei Capital, an investment firm focused on early-stage biopharmaceutical companies. In 2023 he served as Chief Financial Officer and Chief Business Officer of Ocugen, Inc. (NASDAQ: OCGN) and prior to that, he served as Chief Operating Officer and Chief Business Officer for 180 Life Sciences Corp. (NASDAQ: ATNF) from November 2021 to January 2023. Before joining 180 Life Sciences and since 2019, Mr. Vu has provided services as a consultant/independent contractor through his own consulting firm, Melius BioPharma Consulting. Under Melius, he has served in various capacities for the following companies: 1) LS Associates, a life science services firm and a member company of LifeSci Partners, as an interim C-suite consultant since July 2020; 2) Baleena Bioscience, Inc., a biomedical company focused on healthspan, as CEO from April 2021 through October 2021; and 3) Solganick & Co., a technology investment banking firm, as Managing Director and Co-Head of Healthcare IT, from September 2019 through October 2021 and again from August 2024 through February 2025. From September 2016 to August 2019, Mr. Vu served as Vice President and Head of Strategy and Corporate & Business Development at Opiant Pharmaceuticals, Inc., a publicly-traded specialty pharmaceutical company acquired by Indivior PLC (LSE: INDV.L). Prior to Opiant, he held leadership roles of increasing responsibility at Impax Laboratories, Inc., Elevance Health, Inc. (formerly Anthem, Inc.) and Amgen, Inc. Earlier in his career, he worked in the healthcare corporate finance and M&A departments at bulge-bracket investment banks, including Morgan Stanley and Goldman Sachs. Mr. Vu obtained his MS in Legal Studies from Cornell University Law School and BA in Economics from UCLA, graduating summa cum laude with College Honors and Economics Departmental Honors. He is also a Certified Treasury Professional (inactive).
What is Quan Anh Vu's net worth?
The estimated net worth of Quan Anh Vu is at least $79.88 thousand as of December 26th, 2025. Vu owns 1,500 shares of Monopar Therapeutics stock worth more than $79,875 as of May 1st. This net worth estimate does not reflect any other assets that Vu may own. Learn More about Quan Anh Vu's net worth.
How do I contact Quan Anh Vu?
Has Quan Anh Vu been buying or selling shares of Monopar Therapeutics?
Quan Anh Vu has not been actively trading shares of Monopar Therapeutics within the last three months. Most recently, on Friday, December 26th, Quan Anh Vu bought 1,500 shares of Monopar Therapeutics stock. The stock was acquired at an average cost of $69.95 per share, with a total value of $104,925.00. Following the completion of the transaction, the chief financial officer now directly owns 1,500 shares of the company's stock, valued at $104,925. Learn More on Quan Anh Vu's trading history.
Who are Monopar Therapeutics' active insiders?
Are insiders buying or selling shares of Monopar Therapeutics?
In the last twelve months, Monopar Therapeutics insiders bought shares 1 times. They purchased a total of 1,500 shares worth more than $104,925.00. In the last twelve months, insiders at the sold shares 4 times. They sold a total of 592,733 shares worth more than $36,700,226.69. The most recent insider tranaction occured on December, 26th when CFO Quan Anh Vu bought 1,500 shares worth more than $104,925.00. Insiders at Monopar Therapeutics own 20.5% of the company.
Learn More about insider trades at Monopar Therapeutics. Information on this page was last updated on 12/26/2025.
